Compare NPWR & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NPWR | SWKH |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Diversified Financial Services |
| Sector | Energy | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.9M | 205.9M |
| IPO Year | N/A | 1999 |
| Metric | NPWR | SWKH |
|---|---|---|
| Price | $2.14 | $17.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 822.2K | 5.3K |
| Earning Date | 03-09-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | N/A | ★ 1.85 |
| Revenue | N/A | ★ $40,149,000.00 |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.31 |
| Revenue Growth | 42.86 | ★ 62.38 |
| 52 Week Low | $1.48 | $13.17 |
| 52 Week High | $8.87 | $20.49 |
| Indicator | NPWR | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | N/A |
| Support Level | $1.96 | N/A |
| Resistance Level | $2.43 | N/A |
| Average True Range (ATR) | 0.14 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 12.12 | 0.00 |
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.